Literature DB >> 29629769

Developing Equipotent Teixobactin Analogues against Drug-Resistant Bacteria and Discovering a Hydrophobic Interaction between Lipid II and Teixobactin.

Yu Zong1, Xiuyun Sun1,2, Hongying Gao1,2, Kirsten J Meyer3, Kim Lewis3, Yu Rao1.   

Abstract

Teixobactin, targeting lipid II, represents a new class of antibiotics with novel structures and has excellent activity against Gram-positive pathogens. We developed a new convergent method to synthesize a series of teixobactin analogues and explored structure-activity relationships. We obtained equipotent and simplified teixobactin analogues, replacing the l- allo-enduracididine with lysine, substituting oxygen to nitrogen on threonine, and adding a phenyl group on the d-phenylalanine. On the basis of the antibacterial activities that resulted from corresponding modifications of the d-phenylalanine, we propose a hydrophobic interaction between lipid II and the N-terminal of teixobactin analogues, which we map out with our analogue 35. Finally, a representative analogue from our series showed high efficiency in a mouse model of Streptococcus pneumoniae septicemia.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29629769     DOI: 10.1021/acs.jmedchem.7b01241

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  12 in total

Review 1.  Recent Progress in Natural-Product-Inspired Programs Aimed To Address Antibiotic Resistance and Tolerance.

Authors:  Yasmeen Abouelhassan; Aaron T Garrison; Hongfen Yang; Alejandra Chávez-Riveros; Gena M Burch; Robert W Huigens
Journal:  J Med Chem       Date:  2019-04-18       Impact factor: 7.446

2.  Escaping mechanisms of ESKAPE pathogens from antibiotics and their targeting by natural compounds.

Authors:  Ragi Jadimurthy; Shilpa Borehalli Mayegowda; S Chandra Nayak; Chakrabhavi Dhananjaya Mohan; Kanchugarakoppal S Rangappa
Journal:  Biotechnol Rep (Amst)       Date:  2022-04-04

3.  Design, Synthesis, and Study of Lactam and Ring-Expanded Analogues of Teixobactin.

Authors:  Hyunjun Yang; Arthur V Pishenko; Xingyue Li; James S Nowick
Journal:  J Org Chem       Date:  2019-12-09       Impact factor: 4.354

4.  X-ray Crystallographic Structure of a Teixobactin Derivative Reveals Amyloid-like Assembly.

Authors:  Hyunjun Yang; Michał Wierzbicki; Derek R Du Bois; James S Nowick
Journal:  J Am Chem Soc       Date:  2018-10-12       Impact factor: 15.419

5.  The Killing Mechanism of Teixobactin against Methicillin-Resistant Staphylococcus aureus: an Untargeted Metabolomics Study.

Authors:  Maytham Hussein; John A Karas; Elena K Schneider-Futschik; Fan Chen; James Swarbrick; Olivia K A Paulin; Daniel Hoyer; Mark Baker; Yan Zhu; Jian Li; Tony Velkov
Journal:  mSystems       Date:  2020-05-26       Impact factor: 6.496

6.  Structural studies suggest aggregation as one of the modes of action for teixobactin.

Authors:  Carl Öster; Grzegorz P Walkowiak; Dallas E Hughes; Amy L Spoering; Aaron J Peoples; Anita C Catherwood; Julie A Tod; Adrian J Lloyd; Torsten Herrmann; Kim Lewis; Christopher G Dowson; Józef R Lewandowski
Journal:  Chem Sci       Date:  2018-09-20       Impact factor: 9.825

7.  Probing key elements of teixobactin-lipid II interactions in membranes.

Authors:  Po-Chao Wen; Juan M Vanegas; Susan B Rempe; Emad Tajkhorshid
Journal:  Chem Sci       Date:  2018-07-20       Impact factor: 9.825

8.  Therapeutic compounds targeting Lipid II for antibacterial purposes.

Authors:  Jakob J Malin; Erik de Leeuw
Journal:  Infect Drug Resist       Date:  2019-08-23       Impact factor: 4.003

9.  Gram-scale total synthesis of teixobactin promoting binding mode study and discovery of more potent antibiotics.

Authors:  Yu Zong; Fang Fang; Kirsten J Meyer; Liguo Wang; Zhihao Ni; Hongying Gao; Kim Lewis; Jingren Zhang; Yu Rao
Journal:  Nat Commun       Date:  2019-07-22       Impact factor: 14.919

10.  Mode of action of teixobactins in cellular membranes.

Authors:  Rhythm Shukla; João Medeiros-Silva; Anish Parmar; Bram J A Vermeulen; Sanjit Das; Alessandra Lucini Paioni; Shehrazade Jekhmane; Joseph Lorent; Alexandre M J J Bonvin; Marc Baldus; Moreno Lelli; Edwin J A Veldhuizen; Eefjan Breukink; Ishwar Singh; Markus Weingarth
Journal:  Nat Commun       Date:  2020-06-05       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.